DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA411271
Title:
Assessment of the Tendency of SERMS (Tamoxifen and Raloxifene) to Induce a Metastatic Phenotype in Breast Cancer in a Chemopreventive Setting
Descriptive Note:
Annual rept. 1 Jun 2001-31 May 2002
Corporate Author:
NOTRE DAME UNIV IN
Report Date:
2002-06-01
Pagination or Media Count:
41.0
Abstract:
The overall goal of this research is to determine whether the selective estrogen receptor modulator SERM, tamoxifen can induce a metastatic phenotype in non-invasive estrogen receptor positive ER MCF-7 cells grown as orthotopic xenografts in nude mice. The experiments in this proposal were designed to compare the spread of MCF-7 with that of a well characterized estrogen receptor negative metastatic cell line MDA-MB0- 345 tagged with green fluorescent protein. Pilot studies have shown that tamoxifen can induce the metastatic spread of MCF-7 at least as far as the lymph nodes. Due to morbidity problems unrelated to tumor progression, the major experiment was stopped before it was possible to establish whether MCF-7 can also metastasize to other more distant organs such as the ling, and liver as is seen with the MDA-MD-435 cells. These data suggest that tamoxifen can induce lymphatic spread of non-invasive cell line and promotes the survival of the tumor cells in the lymphatic system. We have not yet established whether hematogenous spread of the ER cells can also occur.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
